Phathom Pharmaceuticals (PHAT) Set to Announce Quarterly Earnings on Thursday

Phathom Pharmaceuticals (NASDAQ:PHAT) is scheduled to release its earnings data before the market opens on Thursday, August 8th. Analysts expect Phathom Pharmaceuticals to post earnings of ($1.38) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Phathom Pharmaceuticals (NASDAQ:PHAT) last issued its earnings results on Thursday, May 9th. The company reported ($1.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.43) by $0.01. The company had revenue of $1.91 million during the quarter, compared to analysts’ expectations of $2.76 million. On average, analysts expect Phathom Pharmaceuticals to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Phathom Pharmaceuticals Price Performance

NASDAQ PHAT opened at $10.89 on Wednesday. The business has a 50 day moving average price of $11.00 and a 200 day moving average price of $9.90. The company has a market capitalization of $637.45 million, a P/E ratio of -2.47 and a beta of 0.68. Phathom Pharmaceuticals has a 1-year low of $6.07 and a 1-year high of $17.02.

Insider Buying and Selling

In other news, COO Azmi Nabulsi sold 10,901 shares of Phathom Pharmaceuticals stock in a transaction on Monday, July 15th. The stock was sold at an average price of $11.72, for a total value of $127,759.72. Following the completion of the sale, the chief operating officer now owns 240,421 shares of the company’s stock, valued at $2,817,734.12. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, insider Terrie Curran sold 33,848 shares of Phathom Pharmaceuticals stock in a transaction on Monday, July 15th. The stock was sold at an average price of $11.72, for a total value of $396,698.56. Following the transaction, the insider now owns 377,734 shares in the company, valued at $4,427,042.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Azmi Nabulsi sold 10,901 shares of the business’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $11.72, for a total value of $127,759.72. Following the sale, the chief operating officer now owns 240,421 shares of the company’s stock, valued at approximately $2,817,734.12. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 49,074 shares of company stock worth $575,147. 24.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on PHAT. HC Wainwright reissued a “buy” rating and issued a $28.00 price objective on shares of Phathom Pharmaceuticals in a research note on Friday, July 19th. Stifel Nicolaus began coverage on Phathom Pharmaceuticals in a report on Friday, May 3rd. They set a “buy” rating and a $24.00 target price on the stock. Finally, Needham & Company LLC restated a “buy” rating and issued a $26.00 price objective on shares of Phathom Pharmaceuticals in a research report on Friday, July 26th.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.